Literature DB >> 18162290

Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression.

Li B Li1, Maggie C Louie, H-W Chen, June X Zou.   

Abstract

Overexpression of ACTR/AIB1 is frequently found in different cancers with distant metastasis. To address its possible involvement in tumor metastasis, we performed invasion assays to examine the effect of ACTR alteration on the invasiveness of breast cancer cells (MDA-MB-231 or T-47D) and found that high levels of ACTR are required for their strong invasiveness. Molecular analysis indicates that ACTR functions as a coactivator of AP-1 to up-regulate the expression of matrix metalloproteinases such as MMP-7 and MMP-10 and reduce cell adhesion to specific extracellular matrix proteins. These novel findings provide a mechanistic link between ACTR and MMPs, and suggest that ACTR may also play an important role in cancer progression by facilitating tumor invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18162290     DOI: 10.1016/j.canlet.2007.11.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

Review 1.  Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis.

Authors:  John P Lydon; Bert W O'Malley
Journal:  Endocrinology       Date:  2010-11-03       Impact factor: 4.736

2.  Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis.

Authors:  Si Guo; JingJing Xu; Rui Xue; YuQiong Liu; HaiBo Yu
Journal:  Int J Clin Oncol       Date:  2013-03-30       Impact factor: 3.402

3.  ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion.

Authors:  Weiwen Long; Charles E Foulds; Jun Qin; Jian Liu; Chen Ding; David M Lonard; Luisa M Solis; Ignacio I Wistuba; Jun Qin; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

Review 4.  The role of SRC-3 in human breast cancer.

Authors:  Ondrej Gojis; Bharath Rudraraju; Mihir Gudi; Katy Hogben; Sami Sousha; R Charles Coombes; Charles R Coombes; Susan Cleator; Carlo Palmieri
Journal:  Nat Rev Clin Oncol       Date:  2009-12-22       Impact factor: 66.675

5.  SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration.

Authors:  Weiwen Long; Ping Yi; Larbi Amazit; Heather L LaMarca; Felicity Ashcroft; Rakesh Kumar; Michael A Mancini; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

6.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

Review 7.  The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets.

Authors:  Lei Wang; David M Lonard; Bert W O'Malley
Journal:  Horm Cancer       Date:  2016-04-28       Impact factor: 3.869

8.  Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression.

Authors:  Jun Yan; Halime Erdem; Rile Li; Yi Cai; Gustavo Ayala; Michael Ittmann; Li-yuan Yu-Lee; Sophia Y Tsai; Ming-Jer Tsai
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 9.  Steroid receptor coactivator-3 as a potential molecular target for cancer therapy.

Authors:  Jean Ching-Yi Tien; Jianming Xu
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

10.  Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo.

Authors:  Lan Wang; Jueheng Wu; Jie Yuan; Xun Zhu; Hongmei Wu; Mengfeng Li
Journal:  Front Med       Date:  2016-01-20       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.